Clarivate Q2 Loss Deepens on $222M Goodwill Impairment Tied to LS&H Sale
CLVT sits 39% above its 52-week low of $1.66.
Summary
Clarivate's Q2 2026 net loss swelled to $268.6M after a $221.7M goodwill impairment on its Life Sciences & Healthcare unit, which is being sold for $600M. Revenue declined 5.5% to $587.3M, missing estimates.
Key Events · Earnings and Guidance · CLVT
-
Goodwill Impairment Hits Q2
A $221.7M non-cash goodwill impairment on the Life Sciences & Healthcare segment was recorded, as the anticipated sale price under negotiation fell below the unit's carrying value.
-
Revenue Misses Consensus
Q2 revenue of $587.3M missed the $589.7M consensus, down 5.5% year-over-year, driven by product wind-downs and lower transactional activity.
-
Cash Declines, Debt Reduction Continues
Cash and equivalents fell to $217.7M from $329.2M at year-end 2025, while total debt was reduced by $218.4M to $4,251.5M through redemptions and repurchases.
-
Executive Retention and Separation Agreements
A retention agreement for Henry Levy ties RSU vesting to the LS&H sale closing, while IP President Maroun S. Mourad's separation agreement includes a $450K payment.
Analysis · CLVT · Technology
A $221.7 million non-cash goodwill impairment on the Life Sciences & Healthcare segment dominated Clarivate's Q2 results, triggered by the pending $600 million sale of that business. The charge pushed the net loss to $268.6 million, compared with a $72.0 million loss a year ago. Revenue fell 5.5% to $587.3 million, missing consensus, while adjusted EBITDA margin held steady at 42.1%. The balance sheet shows cash declining to $217.7 million from $329.2 million at year-end, though debt reduction continued with $211.1 million in principal payments. The filing also disclosed retention and separation agreements for key executives tied to the LS&H divestiture, underscoring the organizational upheaval. The impairment signals that the negotiated sale price is below the unit's carrying value, a negative mark-to-market on a major strategic move.
At the time of this filing, CLVT was trading at $2.31 on NYSE in the Technology sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $1.66 to $4.77. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.